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prostate cancer) (C60-63), 10.7% had malignant neoplasms of digestive organs (C15-
26) and 8,4% showed malignant neoplasms of ill-defined, secondary and unspecified 
sites (C76-80). The outpatient diagnosis rate for CLL was 94.9%, inpatient rate 0.6% 
and in-and outpatient rate 4.6%. Overall, 266 of 1,405 pts (18.9%) (175 men [65.8%], 91 
women [34.2%]) received chemotherapy in 2012 (ATC Code L01* 74.1%, PZN 9999092 
23.0%, OPS 854* 2.9%). Most patients received outpatient treatment (94.0%), with 5.3% 
of patients received both out- and inpatient treatment and 0.7% inpatient treat-
ment. The most commonly used treatments were rituximab (26.7%), bendamustine 
(20.2%), chlorambucil (11.1%), cyclophosphamide (7.7%), fludarabine (6.2%) and other 
treatments (28.1%). ConClusions: The majority of patients being diagnosed with 
CLL did not require treatment within a time period of a year. Approximately 1/3 
of patients had a second malignancy, predominantly skin cancer. Treatment was 
primarily composed of chemotherapy or chemoimmunotherapy.
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objeCtives: To estimate the annual number of patients in France with Acute 
Myeloid Leukemia (AML) and MyeloDysplasic Syndrom (MDS) and treated with 
intensive chemotherapy susceptible to induce neutropenia. Methods: French hos-
pital databases named PMSI record medical information about all the hospitaliza-
tions performed annually in France. From 2006 to 2012, databases allow linking the 
stays over time of a given patient with an anonymous number. In this study, PMSI 
databases were used to identify patient, aged more than 15, with diagnosis of AML 
or MDS and who were alive during the year 2012. Then, patients who underwent 
hospital stays for chemotherapy during more than 5 days were identified and con-
sidered as neutropenic according to experts opinions. Results: Since 2006, 51,386 
patients with at least one diagnosis of AML or MDS and aged more than 15 were 
identified, from which only, 16,006 had at least one hospital stay in 2012 and 3,468 
were hospitalized more than 5 days for chemotherapy. Among those patients, 55.2% 
were male, mean age was 60.4 years, 30% died during a hospital stay and 19% (664) 
were bone marrow grafted during the year 2012. These patients had 1.8 stays for 
chemotherapy per year with average chemotherapy duration of 27 days. Two third 
of these patients (34%) were diagnosed in 2012 and 23% in 2011. ConClusions: 
Among the 16,006 patients diagnosed AML or SMD and hospitalized in France in 
2012, 3, 468 (21%) received intensive chemotherapy inducing neutropenia, putting 
them at high risk of invasive fungal infection.
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objeCtives: To estimate the number of patients receiving Allogeneic Stem Cell 
Transplant (ASCT) and presenting with graft versus host disease (GVHD) in 2012 in 
France. Methods: French hospital databases named PMSI record medical informa-
tion about all the hospitalizations performed annually in France. From 2006 to 2012, 
databases allow linking the stays of a given patient over time with an anonymous 
number. In this study, PMSI databases were used to identify patient, aged more 
than 15, with allogeneic stem cell transplant through adequate Diagnosis Related 
Group and who were alive, hospitalized during the year 2012. Patients with diag-
nosis of GVHD or typical diagnoses of GVHD symptoms (sclerodermia, diarrhea, 
mucitis and keratitis) were identified. Results: Since 2006 to 2012, 9,855 patients 
received allogeneic stem cell transplant in France of which 3,469 died during a 
hospitalization over the period, with an annual death rate stable around 20%. In 
2012, 3,842 ASCT patients aged more than 15 were hospitalized at least once, and 
the proportion with GVHD was estimated to 40% (1,574). Acute GVHD diagnosis or 
typical GVHD symptoms occurring less than 100 days after grafting appeared in 
274 patients and chronic GVHD was diagnosed in 1300 patients. Mean age was 47.8, 
61.4% were male and 22% of these patients died during a stay in 2012. Among the 
ASCT patients hospitalized in 2012, only 5% were grafted in 2006 and this figure 
regularly increased with the year of the procedure to reach 35% grafted in 2012, cor-
responding to a mean annual mortality rate of around 20%. ConClusions: Among 
the 3,842 ASCT patients hospitalized in France in 2012, 1,574 (40%) presented GVHD, 
putting them at higher risk of immunosuppression and invasive fungal infection, 
but also at higher risk of death.
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objeCtives: From among the consequences of the obesity very considerable the 
emotional and distressful disturbances with which it grew fat children day, than 
day they fight. Assessing a what kind of measure the sport influences it on was our 
aim the nutritional and the mood life, furthermore, that the obesity influences the 
learning and the mood life. Methods: We made a questionnaire survey in the 
primary schools of Szekszárd, 13-14 year ones among students. Inclusion it was a 
criterion that only 7-8. are class children may have taken a part in the examination, 
furthermore without parents consent, and sufferers may not have taken a part in 
the examination only in a serious illness. All element 149 heads. At the compila-
tion of the questionnaire used Helena (Healthy Lifestile in Europe by Nutritrion in 
Adolescence) name from a project for us essential questions, and we complemented 
it their edited our questionnaire implied altogether 150 questions with questions, 
6 years, would be 34% lower. ConClusions: Treatment with nilotinib is expected 
to result in better health outcomes, with more patients achieving TFR. This initial 
TKI investment should reflect itself in long term economic benefits.
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objeCtives: Familial Amyloid Polyneuropathy (FAP) is a rare, rapidly progressive, 
debilitating and life-threatening neurodegenerative disease. Pre-symptomatic 
genetic testing (PST) can contribute to reduce FAP prevalence, informing carriers 
about risk of transmission to offspring’s and available reproductive options such as 
Pre Natal Diagnosis (PND) or Pre Implantation Genetic Diagnosis (PGD). This study 
aims to describe FAP carrier’s reproductive options after PST and to analyse its 
socio-demographic determinants. Methods: Data from a cohort of 145 FAP carriers 
that underwent PST at Medical Genetics Unit (HP/CHUC – Portugal, 2000-2012) was 
used to analyse reproductive options of FAP carrier’s. An econometric logistic model 
was specified to identify determinants for natural reproduction option. Results: 
The subjects were mainly women (55%) with mean age of 35 years (SD= 15) at PST 
entry. Most participants were in a relationship 92/145 (63%) and mean number years 
of education was 9 years (SD= 14). 75/145 (52%) of subjects were already parents, 
reporting a total of 144 children. 21/145 (14%) subjects decided not to have offspring 
following their positive test result. No child adoption was reported. 27/145 (19%) 
of subjects report offspring posteriori to PST: 19/27 (70%) subjects undergo natural 
reproduction and 8/27 (30%) reproduction with PND or PGD support. A total of 9 off-
spring non-FAP carriers (with PND/PGD) and 24 offspring from natural reproduction 
were observed until data collection. The logistic regression for decide on natural 
reproduction confirms statistical significance (p-value< 0.05) for only two variables: 
being in relationship and having previous children. No statistical significance was 
observed for gender, age at PST or number of education years. ConClusions: 
There is evidence of a high proportion of carriers with offspring’s when initiate 
PST and high proportion of natural reproduction within FAP carriers after PST. An 
ethical physiological case-by-case approach is essential to learn more about the 
determinants for preventing FAP offspring transmission.
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objeCtives: To describe the prevalence of outpatient prescription opiate use 
among patients with Commercial, Medicare Supplemental, or Medicaid insurance 
in the US after 2010. Methods: Patients were identified using the Truven Health 
Commercial and Medicare Supplemental databases from 2010-2013 and Medicaid 
Multi-State databases from 2010-2012. We estimated the proportion of patients with 
at least one outpatient opiate prescription for each calendar year among patients 
with continuous medical and pharmacy enrollment for the entire calendar year, 
stratified by insurance type and age (< 18, 18-64, 65+). Average opiate days supply 
per calendar year was also described. Results: On average, a total of 32.9 million 
(m) patients were included in each calendar year analysis with an average of 6.7m 
Commercially-insured children, 20.2m Commercially-insured non-elderly adults, 
2.5m Medicare Supplemental adults (age 65+), 2.6m Medicaid-insured children and 
0.8m Medicaid-insured adults per year. Among commercially-insured non-elderly 
adults, the prevalence of opiate prescriptions decreased from 25.1% to 23.4% from 
2010 to 2013 (p< 0.001) with a similar decrease among Medicare Supplemental 
patients (29.5% to 27.6%, p< 0.001). Among Medicaid adults, opiate prescription 
prevalence was lower prevalence in 2012 (38.9%) than in 2010 (44.1%) or 2011 (45.2%). 
Among children (age < 18), opiate prescription prevalence use was slightly higher for 
Medicaid than commercially-insured children (9.9% versus 7.4%, p< 0.001); opiate 
prescription prevalence dropped by 15.3% among commercially-insured patients 
from 2010 to 2013 (p< 0.001) and by 12.1% among Medicaid children from 2010 to 2012 
(p< 0.001). Average annual days supply increased over time among Medicaid adults 
(92.8 to 100.5 days), commercially-insured non-elderly adults (41.7 to 44.5 days) and 
Medicare Supplemental adults (65.9 to 68.6 days); days supply per year was steady 
among children (calendar year range: 7.5-9.1). ConClusions: There were modest 
reductions in the prevalence of prescription opiate use from 2010-2013. Further and 
more detailed monitoring is needed to parallel efforts to curtail inappropriate use.
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objeCtives: No national registries for chronic lymphocytic leukaemia (CLL) exist 
in Germany. The objective of this analysis was to examine the number of patients 
with CLL diagnosed (with or without other diagnoses of cancer) and to character-
ize the types of treatment being utilized and care settings using sickness funds 
claim data. Methods: This analysis evaluates data from 1,771,225 beneficiaries 
in 2012 from different statutory sickness funds. Patients with CLL were identified 
by ICD-10 C91.1*, oncological co-diagnoses by ICD-10 C00-79; D37-48 and chemo-
therapy by Anatomical Therapeutic Chemical (ATC) Code L01*, pharmacy number 
(PZN) 9999092 and/or operating and procedure code (OPS) 854*. Results: In total, 
1,405 patients with a diagnosis C91.1* (CLL) were identified (prevalence 79/100,000) 
with 60.2% were male and 39.8% female. Overall, 32.2% of patients with CLL had a 
co-diagnosis with another cancer; 25.1% melanoma (C43-44), 21.3% had neoplasms 
with unknown behaviour (D37-48), 11.8% had malignant male GU neoplasms (90% 
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estimate was based on prevalence data for URDs for which patented drugs are cur-
rently available and for which drugs are in clinical development and hence may 
be expected to be launched in the foreseeable future. A power function was used 
to estimate the relation between (decreasing) prevalence and (increasing) cost per 
patient. For drugs in development, we applied phase duration data and attrition 
rates from the Tufts Center for the Study of Drug Development database. Results: 
A total of 18 drugs under patent protection for non-oncological URDs were identi-
fied. Furthermore, 29 drugs for non-oncological URDs under development that have 
the potential of reaching the market by 2021 were found. Total budget impact over 10 
years was estimated to be € 14,112 and € 4,965 million for approved and pipeline URD 
drugs, respectively (total: € 19,077 million). Relative to total pharmaceutical expendi-
tures in Europe, spending on drugs for URDs is estimated to rise from 0.7% at present 
to 1.6% in 2021. Univariate sensitivity analyses and extreme scenario analyses sug-
gesting robustness of this projection will be presented. ConClusions: Our analysis 
does not support concerns regarding an uncontrolled growth in expenditures for 
drugs for URDs. Nevertheless, continuous monitoring of the budget impact as an 
input to rational policy making is recommended.
PSY24
Budget iMPAct oF orPhAn drugS in the netherlAndS in the Period 
2006-2012
Kanters T.A., Steenhoek A., Hakkaart L.
Erasmus University Rotterdam, Rotterdam, The Netherlands
objeCtives: The relatively low budget impact of orphan drugs is often used as 
an argument in reimbursement decisions. However, overall, the budget impact of 
orphan drugs can still be substantial. In this study, we assess the uptake and budget 
impact of orphan drugs in the Netherlands. Methods: We examined the number 
of orphan drugs, the number of patients and budget impact of orphan drugs in the 
Netherlands in the period 2006 to 2012, both for inpatient and outpatient orphan 
drugs. Budget impact was provided in absolute numbers and relative to total phar-
maceutical spending. Results: The number of orphan drugs and patients treated 
increased substantially over the period studied. Overall, budget impact increased 
substantially over a period of six years, both in absolute terms (426% increase) as 
well as relative to total pharmaceutical spending (378% increase). Growth rates 
decreased over time. In 2012, 17% of available drugs had an individual budget impact 
of more than € 10 million per year. ConClusions: Individual budget impact of 
orphan drugs is often limited, although exceptions exist. However, in total, the 
budget impact of orphan drugs is considerable and has grown substantially over 
the years. This could potentially influence reimbursement decisions for orphan 
drugs in the future.
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objeCtives: Biosimilar infliximab has been approved by EMA for the management 
of inflammatory autoimmune disorders including rheumatoid arthritis (RA), anky-
losing spondylitis (AS), Crohn’s disease, ulcerative colitis (UC), psoriatic arthritis 
(PsA), and psoriasis based on quality, safety and efficacy profiles comparable to inf-
liximab. The aim of this study was to evaluate the five-year budget impact of intro-
ducing biosimilar infliximab in the management of RA, AS, Crohn’s disease, UC, PsA, 
and psoriasis from the health care system perspective. Methods: An Excel-based 
budget impact model was developed. The numbers of patients eligible for infliximab 
were calculated based on disease prevalence rates in Germany, Italy, Belgium, the 
Netherlands and the United Kingdom. The price of biosimilar infliximab is not yet 
known; therefore three discount scenarios versus infliximab (10%, 20%, and 30%) 
were applied. Market share was assumed to be 25% in the first year in all scenarios. 
Annual market share growth was varied in each of the scenarios at 20%, 30% and 
40%, respectively. Results: The combined net budget savings for Germany, Italy, 
Belgium, the Netherlands and the United Kingdom in the first year were € 17.8, € 35.5 
and € 53.3 million for the 10%, 20% and 30% price discount scenarios, respectively. 
Over a 5 year period the net budget savings were € 132.8, € 322.8 and € 532.8 million 
for the 10%, 20% and 30% price discount scenarios, respectively. ConClusions: 
The introduction of biosimilar infliximab as a treatment option for patients with RA, 
AS, Crohn’s disease, UC, PsA, and psoriasis could achieve substantial cost savings 
for health care systems. In the price discount scenarios tested, the total combined 
savings across Germany, Italy, Belgium, the Netherlands and the United Kingdom 
over a 5 year period ranged from € 132.8 million to € 532.8 million. The net budget 
impact was highly sensitive to market uptake rates and the price discount applied.
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objeCtives: To estimate budget impact analysis (BIA) of belimumab plus stand-
ard of care (SoC) comparing the SoC alone in the treatment of patients suffering 
from systemic lupus erythematosus (SLE). Methods: BIA was conducted of the 
belimumab treatment plus SoC vs SoC alone. Costs of treatments in both groups 
contained following direct medical costs: costs of drugs and administration, costs 
of diagnostic laboratory and instrumental procedure, costs of inpatient and outpa-
tient visits, costs of SLE complications and also adverse event costs. A five-year time 
horizon was used. All costs in both groups were estimated to their present value 
using a 5 % discount rate. Results: Costs of the course of belimumab therapy were 
2,118,449 RUB/ 45,581 EUR for 5 years but the difference in the required budget funds 
between belimumab treatment groups and SoC alone treatment group amounted to 
1,876,965 RUB/ 40,385 EUR for 5 years with a 5 % discount rate. The decrease of the 
difference in the required budget funds between these two groups was due to a lower 
so. Results: Our 1. hypothesis, that the children with normal weight move much, 
than their obese companions, not proven true (p= 0,778). It was the next supposition 
that less are truth with a subject for the students with normal weight they have 
difficulties, than for the obese students. According to the examination, the normal 
one and the obese child with a subject truth in the look of difficulty, we found a 
significant difference (p= 0,015). The third hypothesis, that, in the obese group taller 
the anxious children’s proportion, than the did not grow fat in a group, not proven 
true. The overweight children (n= 46, medium= 109, 76) anxiety with a significantly 
bigger degree was not showed based on the scale the normal one tápláltsági state 
at students (n= 95, medium= 104, 56 dot, p= 0,515). ConClusions: The enrolled 
students showed no significant difference between the observed parameters of the 
overweight and sporting habits.
SYSteMic diSorderS/conditionS – cost Studies
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objeCtives: Bispectral Index (BIS) monitoring systems monitor spontaneous elec-
troencephalography, track sedative drug effects and help guide anaesthetic admin-
istration. Evidence shows such monitoring enables savings on anaesthesia and 
reduces adverse events compared with monitoring clinical signs only. However, the 
cost-effectiveness of monitors is uncertain. Methods: A cost-effectiveness model 
and budget impact analysis were developed to compare the outcomes of monitor-
ing the depth of anaesthesia with BIS monitors compared with standard clinical 
monitoring. Over a five-year period, the model estimated the incremental cost per 
quality-adjusted life year (QALY) and incremental number of adverse events avoided 
in theatres with anaesthetists using BIS monitors compared with standard care. 
Data values were obtained from peer-reviewed literature. Subgroup analysis was 
conducted for an elderly patient group. Sensitivity analyses explored uncertainty 
in the model. A budget impact model examined the financial impact of adopting 
BIS monitors across the UK. Results: The modelled results showed that using BIS 
monitors dominated clinical observation of signs and use of electrocardiograph 
and other devices, being cost saving by £82 per operation in the adult population, 
whilst improving QALYs by 0.016 per patient. The budget impact analysis showed 
a cumulative saving of over £136 million if theatres in the UK adopted a phased 
increase in monitor use such that 1.35 million surgical procedures were conducted 
using these monitors in five years time. ConClusions: Adopting BIS monitors 
is cost-effective and results in substantial cost savings compared with observing 
clinical signs plus conventional devices only.
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objeCtives: To estimate the costs of drug supply for registered rare diseases (RD) 
patients in Russia in 2013. Methods: The study included two steps: 1) the analysis 
of the current situation with financing of drugs for RD patients in Russia in 2013 
and 2) estimating the unmet needs - necessary weighted average costs (nWAC) for 
a pathogenetic pharmacotherapy of registered patients with RD in the same year. 
Number of registered patients with 24 RD listed in the Government Regulation of 
Russian Federation № 403 from April 26, 2012 was estimated for the studied year. 
Number of registered patients and actual financing has been received from the 
database of regional public health services. The nWAC for expensive pathogenetic 
pharmacotherapy of patients with 24 RD were calculated on the basis of stand-
ards of therapy and experts’ survey results. The current situation with financing 
of RD drugs in Russia in 2013 was compared with unmet needs (nWAC). Results: 
4.4 billion rubles ($125.7 million) were spent from regional budgets in Russia for 
11,173 patients (0.008% from all population of Russia) with 24 RD in 2013. The larg-
est patient group with 3,460 patients was a classic phenylketonuria group. The 
prognostic annual nWAC for pharmacotherapy of the most expensive patient with 
type VI mucopolysaccharidosis were 40.9 million rubles ($1.2 million) per child 
and 71.5 million rubles ($2.0 million) per adult. The nWAC for pharmacotherapy 
of registered patients with 24 RD in 2013 were 15.7 billion rubles ($448.6 million). 
The annual nWAC for pharmacotherapy of the most expensive disease (idiopathic 
thrombocytopenic purpura (Evans syndrome) was estimated as 2.9 billion rubles 
($82.8 million) per group of 2,700 patients. ConClusions: The state financing of 
pharmacotherapy for patients with 24 RD in Russia should be increased approxi-
mately in 3.5 times to fulfill the unmet needs.
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objeCtives: Ultra‐rare disorders (URDs) have been defined by a prevalence of less 
than 1 per 50,000 persons. On a per patient basis, the annual acquisition costs of 
drugs for URDs can be very high, and there have been concerns that expenditures 
for these products might escalate in the future. The goal of this study was therefore 
to provide a budget impact analysis (BIA) of drugs for ultra-rare non-oncological 
diseases in Europe. Methods: The BIA had a time horizon of 10 years (from 2012 
to 2021) and adopted the perspective of all European payers in combination. The 
